BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 15014039)

  • 1. Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy.
    Seeliger H; Guba M; Koehl GE; Doenecke A; Steinbauer M; Bruns CJ; Wagner C; Frank E; Jauch KW; Geissler EK
    Clin Cancer Res; 2004 Mar; 10(5):1843-52. PubMed ID: 15014039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of metastasis of tumor cells overexpressing thymidine phosphorylase by 2-deoxy-L-ribose.
    Nakajima Y; Gotanda T; Uchimiya H; Furukawa T; Haraguchi M; Ikeda R; Sumizawa T; Yoshida H; Akiyama S
    Cancer Res; 2004 Mar; 64(5):1794-801. PubMed ID: 14996742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of thymidine phosphorylase-mediated angiogenesis and tumor growth by 2-deoxy-L-ribose.
    Uchimiya H; Furukawa T; Okamoto M; Nakajima Y; Matsushita S; Ikeda R; Gotanda T; Haraguchi M; Sumizawa T; Ono M; Kuwano M; Kanzaki T; Akiyama S
    Cancer Res; 2002 May; 62(10):2834-9. PubMed ID: 12019161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-Deoxy-L-ribose inhibits the invasion of thymidine phosphorylase-overexpressing tumors by suppressing matrix metalloproteinase-9.
    Nakajima Y; Haraguchi M; Furukawa T; Yamamoto M; Nakanishi H; Tatematsu M; Akiyama S
    Int J Cancer; 2006 Oct; 119(7):1710-6. PubMed ID: 16646076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-Deoxy-D-ribose, a downstream mediator of thymidine phosphorylase, regulates tumor angiogenesis and progression.
    Nakajima Y; Madhyastha R; Maruyama M
    Anticancer Agents Med Chem; 2009 Feb; 9(2):239-45. PubMed ID: 19199868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab-enhanced antitumor effect of 5-fluorouracil via upregulation of thymidine phosphorylase through vascular endothelial growth factor A/vascular endothelial growth factor receptor 2-specificity protein 1 pathway.
    Liu W; Zhang J; Yao X; Jiang C; Ni P; Cheng L; Liu J; Ni S; Chen Q; Li Q; Zhou K; Wang G; Zhou F
    Cancer Sci; 2018 Oct; 109(10):3294-3304. PubMed ID: 30151975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of angiogenesis and intrahepatic growth of colon cancer by TAC-101.
    Murakami K; Sakukawa R; Sano M; Hashimoto A; Shibata J; Yamada Y; Saiki I
    Clin Cancer Res; 1999 Sep; 5(9):2304-10. PubMed ID: 10499597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenic factor thymidine phosphorylase increases cancer cell invasion activity in patients with gastric adenocarcinoma.
    Yu EJ; Lee Y; Rha SY; Kim TS; Chung HC; Oh BK; Yang WI; Noh SH; Jeung HC
    Mol Cancer Res; 2008 Oct; 6(10):1554-66. PubMed ID: 18922971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of 5-fluorouracil cytotoxicity by human thymidine-phosphorylase expression in cancer cells: in vitro and in vivo study.
    Evrard A; Cuq P; Robert B; Vian L; Pèlegrin A; Cano JP
    Int J Cancer; 1999 Jan; 80(3):465-70. PubMed ID: 9935191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymidine phosphorylase induces angiogenesis in vivo and in vitro: an evaluation of possible mechanisms.
    Sengupta S; Sellers LA; Matheson HB; Fan TP
    Br J Pharmacol; 2003 May; 139(2):219-31. PubMed ID: 12770927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.
    Terashima M; Fujiwara H; Takagane A; Abe K; Irinoda T; Nakaya T; Yonezawa H; Oyama K; Saito K; Kanzaki N; Ohtani S; Nemoto T; Hoshino Y; Kogure M; Gotoh M
    Gastric Cancer; 2003; 6 Suppl 1():71-81. PubMed ID: 12775024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice.
    Koehl GE; Andrassy J; Guba M; Richter S; Kroemer A; Scherer MN; Steinbauer M; Graeb C; Schlitt HJ; Jauch KW; Geissler EK
    Transplantation; 2004 May; 77(9):1319-26. PubMed ID: 15167584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of thymidine phosphorylase, an angiogenic enzyme, in tumor progression.
    Akiyama S; Furukawa T; Sumizawa T; Takebayashi Y; Nakajima Y; Shimaoka S; Haraguchi M
    Cancer Sci; 2004 Nov; 95(11):851-7. PubMed ID: 15546501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer.
    Okumura K; Shiomi H; Mekata E; Kaizuka M; Endo Y; Kurumi Y; Tani T
    Oncol Rep; 2006 Apr; 15(4):875-82. PubMed ID: 16525674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymidine phosphorylase and dihydropyrimidine dehydrogenase activity in colorectal carcinoma and patients prognosis.
    Ikeguchi M; Makino M; Kaibara N
    Langenbecks Arch Surg; 2002 Oct; 387(5-6):240-5. PubMed ID: 12410361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-Ethoxy-2'-deoxyuridine, a novel substrate for thymidine phosphorylase, potentiates the antitumor activity of 5-fluorouracil when used in combination with interferon, an inducer of thymidine phosphorylase expression.
    Schwartz EL; Baptiste N; Megati S; Wadler S; Otter BA
    Cancer Res; 1995 Aug; 55(16):3543-50. PubMed ID: 7627962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer.
    Stephan S; Datta K; Wang E; Li J; Brekken RA; Parangi S; Thorpe PE; Mukhopadhyay D
    Clin Cancer Res; 2004 Oct; 10(20):6993-7000. PubMed ID: 15501979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase.
    Evrard A; Cuq P; Ciccolini J; Vian L; Cano JP
    Br J Cancer; 1999 Aug; 80(11):1726-33. PubMed ID: 10468288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymidine phoshorylase as a target for antiangiogenesis treatment.
    Peters GJ; Bijnsdorp IV; Fukushima M
    Nucleic Acids Symp Ser (Oxf); 2008; (52):629. PubMed ID: 18776537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
    Emura T; Murakami Y; Nakagawa F; Fukushima M; Kitazato K
    Int J Mol Med; 2004 Apr; 13(4):545-9. PubMed ID: 15010854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.